Business context and reporting period
The supplied filing is Reneo Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2022, not OnKure Therapeutics, Inc. Reneo is a clinical-stage pharmaceutical company developing REN001, an oral PPARδ agonist, for primary mitochondrial myopathy and long-chain fatty acid oxidation disorders. It had no approved products and no product revenue.
As of November 3, 2022, Reneo had 24,529,646 common shares outstanding and traded on Nasdaq under the symbol RPHM.
Key financial metrics
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Research and development expense | $9.9 million in 2022 versus $9.3 million in 2021 | $27.3 million versus $21.1 million |
| General and administrative expense | $3.9 million versus $3.4 million | $11.9 million versus $8.1 million |
| Total operating expenses | $13.8 million versus $12.8 million | $39.3 million versus $29.2 million |
| Net loss | $13.0 million versus $12.7 million | $38.4 million versus $29.2 million |
| Net loss per share | $0.53 versus $0.52 | $1.57 versus $1.82 |
| Other income | $0.8 million versus nominal income | $0.9 million versus $0.03 million |
| Net cash used in operating activities | Not separately provided | $31.7 million versus $28.0 million |
There was no revenue, gross profit, or meaningful operating margin because the company had no commercial product sales. Loss from operations was $39.3 million for the first nine months of 2022. Interest income increased with higher rates on cash and investments.
- Cash and cash equivalents at September 30, 2022: $62.1 million.
- Short-term investments: $53.9 million.
- Total cash, cash equivalents, and short-term investments: approximately $116.1 million.
- Total assets: $122.5 million; total liabilities: $10.5 million; stockholders’ equity: $112.0 million.
- Accumulated deficit: $123.1 million.
- The filing reports no debt financing or outstanding debt; operating lease liabilities totaled $1.4 million.
Material changes versus the prior comparable period
- Nine-month research and development expense increased $6.3 million, primarily because of STRIDE pivotal-trial activity, LC-FAOD Phase 1b work, manufacturing costs, and additional personnel.
- Nine-month general and administrative expense increased $3.8 million, mainly from higher public-company professional services, insurance, and personnel costs.
- Nine-month net loss increased $9.2 million to $38.4 million, despite a $0.9 million increase in other income.
- Operating cash use increased $3.8 million to $31.7 million.
- Cash and cash equivalents declined $62.5 million during the first nine months, partly because the company invested funds in short-term investments. Financing provided only $0.1 million in 2022, compared with $132.3 million in 2021 from the IPO and preferred-stock financing.
- The company early adopted lease accounting on January 1, 2022, recognizing approximately $1.5 million of right-of-use assets and $1.7 million of lease liabilities at adoption.
Guidance, outlook, risks, contingencies, and unusual items
- Management expected cash, cash equivalents, and short-term investments at September 30, 2022 to fund planned operations into 2024, based on its current operating plan. The company also stated that additional capital will be required.
- An at-the-market facility entered into in May 2022 permits issuance of up to $20.0 million of common stock. No shares had been sold under the facility through September 30, 2022, creating potential future dilution.
- As of November 2022, STRIDE enrollment exceeded 80%; management expected enrollment completion in the first quarter of 2023 and topline results in the fourth quarter of 2023. These are forward-looking expectations and are subject to execution and regulatory risk.
- Management expected FDA feedback on the LC-FAOD program in the first quarter of 2023.
- The company expects continued operating losses and increasing research and development and administrative expenses. It may need equity, debt, collaboration, licensing, or other financing, which may be unavailable or unfavorable.
- COVID-19 previously caused the early closure of a PMM Phase 1b study and may continue to affect enrollment, sites, suppliers, contract research organizations, manufacturing, and regulatory timelines.
- The vTv license agreement requires potential development and regulatory milestone payments of up to $64.5 million, sales-based milestones of up to $30.0 million, and tiered royalties on future net sales. No milestone payments were recorded during the periods presented.
- The CEO performance award has a maximum stated amount of $7.5 million, payable in cash, stock, or a combination, subject to market-value or change-in-control conditions. Its recorded fair value was $66,000 at September 30, 2022 after a $378,000 year-to-date decrease.
- The company reported no material legal proceedings and concluded that disclosure controls and procedures were effective as of September 30, 2022.
- Key risks include dependence on the single product candidate REN001, clinical and regulatory failure, limited patient populations and enrollment challenges, third-party manufacturing and CRO dependence, intellectual-property and license risks, additional financing needs, potential dilution, cybersecurity and data-privacy exposure, and competition.
Most important facts an investor should verify
- Confirm the issuer identity: the supplied filing is for Reneo Pharmaceuticals, not OnKure Therapeutics.
- Verify the company’s cash runway against current spending, trial costs, and the stated need for additional capital.
- Track STRIDE enrollment completion, topline timing, trial results, and any FDA or EMA feedback.
- Review the terms and subsequent use of the $20.0 million ATM facility and the potential effect on share dilution.
- Assess the clinical, regulatory, manufacturing, and intellectual-property risks surrounding REN001 and the vTv license.
- Reconcile subsequent filings for changes in cash, investments, debt or leases, litigation, share count, and management’s revised outlook.